Replies to post #430098 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

It’s called ramping. The point is those two facilities combined could ultimately ramp to 100,000 batches annually once Flaskworks becomes operative. That’s their likely capacity after ramping (if used for that). Not bad.

[HappyLibrarian]

Putting the cart before the horse and wondering why you can never afford to develop the horse is the NWBO way.

First we have seen it with Cognate and now with Advent.

The argument that the FDA and EMA are demanding that a tiny, cash-strapped company with no revenue must develop manufacturing to meet global demand immediately and to do it on pure speculation IF they deign to approve DCVax-L and as a precondition of being seriously considered for approval is laughable.

By that standard only Big Pharmaceutical firms or small firms that partner with them would ever be allowed to get drugs approved.

I guess no one has ever heard of licensed manufacturing which is what inventors do all the time.

Still, without transparency this explanation for the delays is as good as any other.

[biosectinvestor]

Merck won't need to buy Advent. Advent's contract travels with the buyout of NWBO, and Advent is just the contract manufacturer and owns nothing. They could buyout the employment contracts of the employees. They do not need to buyout Advent for any reason speculated upon by this bulletin board.